Financial Contrast: Geovax Labs (GOVX) and Its Competitors

Share on StockTwits

Geovax Labs (OTCMKTS: GOVX) is one of 32 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare Geovax Labs to similar companies based on the strength of its institutional ownership, valuation, profitability, risk, dividends, analyst recommendations and earnings.

Insider and Institutional Ownership

0.1% of Geovax Labs shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Commercial physical research” companies are owned by institutional investors. 2.1% of Geovax Labs shares are owned by insiders. Comparatively, 16.4% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Geovax Labs has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Geovax Labs’ peers have a beta of 4.22, indicating that their average share price is 322% more volatile than the S&P 500.

Profitability

This table compares Geovax Labs and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Geovax Labs -319.03% N/A -433.76%
Geovax Labs Competitors -281.45% -85.75% -34.41%

Earnings & Valuation

This table compares Geovax Labs and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Geovax Labs $1.08 million -$2.17 million -0.67
Geovax Labs Competitors $968.26 million $63.67 million 12.57

Geovax Labs’ peers have higher revenue and earnings than Geovax Labs. Geovax Labs is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Geovax Labs and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geovax Labs 0 0 0 0 N/A
Geovax Labs Competitors 125 591 1364 55 2.63

As a group, “Commercial physical research” companies have a potential upside of 14.32%. Given Geovax Labs’ peers higher probable upside, analysts clearly believe Geovax Labs has less favorable growth aspects than its peers.

Summary

Geovax Labs peers beat Geovax Labs on 9 of the 10 factors compared.

About Geovax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; and CaroGen Corporation. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Conagra Brands  Sets New 52-Week Low at $32.62
Conagra Brands Sets New 52-Week Low at $32.62
Dicks Sporting Goods  Reaches New 1-Year High at $39.75
Dicks Sporting Goods Reaches New 1-Year High at $39.75
Prudential Financial Inc  Shares Sold by Chartwell Investment Partners LLC
Prudential Financial Inc Shares Sold by Chartwell Investment Partners LLC
Chartwell Investment Partners LLC Cuts Holdings in Eagle Materials, Inc.
Chartwell Investment Partners LLC Cuts Holdings in Eagle Materials, Inc.
Crabel Capital Management LLC Sells 2,241 Shares of VanEck Vectors J.P. Morgan EM Local Currency Bond ETF
Crabel Capital Management LLC Sells 2,241 Shares of VanEck Vectors J.P. Morgan EM Local Currency Bond ETF
Chartwell Investment Partners LLC Boosts Stake in PPL Corp
Chartwell Investment Partners LLC Boosts Stake in PPL Corp


Leave a Reply

© 2006-2018 Ticker Report